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The coronavirus disease 2019 (COVID-19) pandemic is caused by rapid spread of different strains of the 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The severity of infection ranges from 
mild, or even asymptomatic, to very severe. Signs and symptoms include fatigue, fever, exanthemas, upper 
respiratory illness, loss of smell and taste, pneumonia, severe acute respiratory syndrome, and multi-organ 
failure. Risk factors for a severe or lethal course include age, male gender, obesity, diabetes, cardiovascular 
disease, and immune suppression1. At the start of the pandemic, the ETFAD shared their position on 
continuation of systemic immune-modulating treatments, including immuno-suppressive therapy, in atopic 
dermatitis (AD) patients during the time of the pandemic2. 
Safe and effective vaccines are urgently needed to control the pandemic and achieve herd immunity. More 
than 50 COVID-19 vaccine candidates are currently in trials.  mRNA vaccines lead to production of 
antigens by host cells, and two (RNA-1273 and BNT162b2) were recently approved in EU member states 
to vaccinate adults against COVID-19. A viral vector-based vaccine (AZD1222) has been approved in the 
United Kingdom, but not yet in the EU. 
National strategic guidelines and recommendations are being developed and utilized to vaccinate initially 
those with increased risk factors for a severe course, as well as those being employed in critical positions. 
This article provides the position of ETFAD members regarding COVID-19 vaccination of adult patients 
with AD being treated with systemic immuno-suppressive medication and biologics. A separate article 
discusses how dermatologist may manage allergic issues. Vaccination particularly against pneumococcus 
and influenza, should be performed as recommended in the guidelines3.
 
The ETFAD acknowledges that
 There is currently no evidence to suggest that AD is an independent risk factor for acquiring 
SARS-CoV-2, or of having a more severe course of COVID-19, above and beyond other important 
co-morbid conditions, such as obesity, cardiovascular disease, and diabetes.
 AD is not a contraindication to vaccination. It is unclear whether SARS-CoV-2 vaccination could 
cause brief AD worsening, but this is not suspected since the vaccination response is mainly T 
helper cell 1 skewed4.   
 Systemic immunosuppressants and JAK-inhibitors used to treat AD may attenuate the vaccination 
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Based on the listed uncertainties and AD disease characteristics3, 7, the risk-benefit ratio of all currently 
approved vaccines appears better than the risk of an infection with SARS-CoV-2, also for AD patients. 
There is no clear evidence to recommend that systemic AD medication is paused before or after COVID-19 
vaccination. Temporary 2-week discontinuation of methotrexate slightly improved the immunogenicity of 
seasonal influenza vaccination in patients with rheumatoid arthritis5, but this may not be relevant to 
mRNA-based vaccines. Clinicians may therefore consider pausing immunosuppressant possible during 
vaccination, typically from the vaccination day until 1 week after for JAK inhibitors and cyclosporine, or 
until 2 weeks after for methotrexate and azathioprine, to possibly improve chances or appropriate 
vaccination response. Alternatively, the lowest dose possible may be used, e.g. 2.5 mg/kg/day cyclosporine, 
1 mg/kg/day azathioprine, and 7.5 mg/week methotrexate. The ETFAD recommends to strictly follow 
guidelines and decisions issued by the local and national health authorities in each country. While patients 
on immunosuppressive drugs for AD will need a case-by-case approach considering the specific drug and 
vaccine product, inadequate antibody response in selected individuals is not a major concern and the 
risk/benefit of vaccination is considered favorable for the overall AD population. At least 3 weeks are 
recommended between the two COVID-19 vaccine doses, which increases the risk of AD flares and loss of 
AD control if the systemic AD medication is paused or reduced in dose for longer periods. Measurement of 
antibodies against SARS-CoV-2 can be done in cases with particular importance of successful 
immunization. If a live vaccine against COVID-19 is registered in the future, our recommendations for the 
use of this vaccine may be different. We encourage registration of COVID-19 AD patients in the ETFAD-
supported SECURE-AD register (www.secure-derm.com), which also captures AD patients’ experiences of 
SARS-CoV-2 vaccination8.
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